Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech bigs float R&D venture

by Rick Mullin
January 16, 2017 | A version of this story appeared in Volume 95, Issue 3

Former Biogen CEO George Scangos is heading a team of drug industry veterans behind Vir Biotechnology, a new company that seeks treatments for infectious disease. The group hopes to employ immune programming to manipulate pathogen-host interactions. Lead investors include Arch Venture Partners and the Bill & Melinda Gates Foundation. Arch, whose co-founder Robert Nelsen conceived of Vir, has committed to invest $150 million. Nelsen says he expects Vir to fund academic research, conduct its own R&D, and spend up to $100 million on individual in-licensing deals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.